{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:48:35Z","timestamp":1791474515539,"version":"4.3.4"},"reference-count":77,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI23\/00924"],"award-info":[{"award-number":["PI23\/00924"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Union Fundaci\u00f3 La Marat\u00f3 de TV3","award":["61\/C\/2025"],"award-info":[{"award-number":["61\/C\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sarcoidosis remains a diagnostic and therapeutic challenge due to its heterogeneous clinical presentation and lack of pathognomonic features. Despite five decades of biomarker research, no single marker has achieved sufficient accuracy for a standalone diagnosis. Traditional biomarkers retain clinical utility when used strategically: High-sensitivity markers (soluble interleukin-2 receptor [sIL-2R], serum amyloid A [SAA], chitotriosidase) excel at confirming disease, while high-specificity markers (lysozyme) better exclude sarcoidosis. Chitotriosidase has emerged as superior to angiotensin-converting enzyme (ACE) for disease monitoring, and sIL-2R remains invaluable for detecting extrapulmonary involvement. However, their limitations necessitate multibiomarker approaches tailored to specific clinical phenotypes. Recent advances address critical unmet needs. High-sensitivity troponin T provides crucial prognostic information in cardiac sarcoidosis, with levels &gt;14\u2009ng\/L predicting adverse outcomes. Novel fibrosis markers, including alveolar nitric oxide, heat shock protein 90\u03b1 (HSP90\u03b1), and advanced Krebs von den Lungen-6 (KL-6) measurement, enable better assessment of disease progression. Prediagnostic inflammatory proteins elevated years before clinical manifestation suggest opportunities for early intervention. Revolutionary omics technologies are transforming biomarker discovery. Extracellular vesicle proteomics identifies treatment-responsive signatures, retrotrans-genomics reveals viral element activation in pathogenesis, and Mendelian randomization distinguishes causal from associative proteins. Integration of multiomics data through machine learning algorithms promises personalized diagnostic and therapeutic strategies. The future of sarcoidosis management lies in intelligent biomarker integration rather than reliance on single tests. Success will be measured by improved patient outcomes through earlier diagnosis, accurate risk stratification, and personalized treatment selection. This paradigm shift from empirical to precision medicine requires continued collaboration between researchers, clinicians, and patients to translate biomarker discoveries into clinical practice.<\/jats:p>","DOI":"10.1055\/a-2741-2030","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:46:01Z","timestamp":1762821961000},"page":"594-601","source":"Crossref","is-referenced-by-count":6,"title":["Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine"],"prefix":"10.1055","volume":"46","author":[{"given":"Maria Belen","family":"Pascual","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Zapata-Huizi","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ramos","sequence":"additional","affiliation":[{"name":"Instituto Nacional del T\u00f3rax, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Francesqui","sequence":"additional","affiliation":[{"name":"Institut de Recerca Sant Pau (IR SANT PAU), Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Alsina-Restoy","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, Barcelona, Spain"},{"name":"CIBER of Respiratory Diseases, Barcelona, Spain"},{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, Barcelona, Spain"},{"name":"CIBER of Respiratory Diseases, Barcelona, Spain"},{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Program, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, Barcelona, Spain"},{"name":"CIBER of Respiratory Diseases, Barcelona, Spain"},{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Facultat de Medicina, University of Vic (UVIC), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"02","key":"ref1","first-page":"736","article-title":"Statement on Sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.","volume":"160","author":"ATS Journals","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"R P Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"E D Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"M Drent","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/1744666X.2016.1196135","article-title":"Biomarkers in sarcoidosis","volume":"12","author":"A Chopra","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1744666X.2019.1568240","article-title":"Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis","volume":"15","author":"M Ramos-Casals","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0002-9343(75)90395-2","article-title":"Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis","volume":"59","author":"J Lieberman","year":"1975","journal-title":"Am J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"J Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccm.2015.08.002","article-title":"Genetics of sarcoidosis","volume":"36","author":"T E Fingerlin","year":"2015","journal-title":"Clin Chest Med"},{"issue":"S 06","key":"ref10","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1513\/AnnalsATS.201707-567OT","article-title":"Application of \u201comics\u201d and systems biology to sarcoidosis research","volume":"14","author":"E D Crouser","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccm.2008.03.004","article-title":"Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas","volume":"29","author":"E Bargagli","year":"2008","journal-title":"Clin Chest Med"},{"issue":"02","key":"ref12","first-page":"329","article-title":"Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis","volume":"120","author":"J Lieberman","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"B Rigat","year":"1990","journal-title":"J Clin Invest"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.rmed.2006.06.025","article-title":"ACE I\/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis","volume":"101","author":"A Kruit","year":"2007","journal-title":"Respir Med"},{"issue":"06","key":"ref15","first-page":"732","article-title":"Assessment of activity in Sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations","volume":"82","author":"H Klech","year":"1982","journal-title":"Chest"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/1346-8138.13792","article-title":"Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement","volume":"44","author":"C Thi Hong Nguyen","year":"2017","journal-title":"J Dermatol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00408-015-9826-3","article-title":"Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: A population-based study","volume":"194","author":"P Ungprasert","year":"2016","journal-title":"Lung"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0002-9343(99)00223-5","article-title":"L\u00f6fgren's syndrome revisited: A study of 186 patients","volume":"107","author":"J Ma\u00f1\u00e1","year":"1999","journal-title":"Am J Med"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.rmed.2014.11.009","article-title":"ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy","volume":"109","author":"A DM Vorselaars","year":"2015","journal-title":"Respir Med"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10875-012-9754-4","article-title":"Human chitotriosidase: A sensitive biomarker of sarcoidosis","volume":"33","author":"E Bargagli","year":"2013","journal-title":"J Clin Immunol"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1515\/jomb-2016-0017","article-title":"Verifying sarcoidosis activity: chitotriosidase versus ACE in sarcoidosis - a case-control study","volume":"35","author":"S Popevi\u0107","year":"2016","journal-title":"J Med Biochem"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.rmed.2014.02.002","article-title":"Serial chitotriosidase measurements in sarcoidosis\u2013two to five year follow-up study","volume":"108","author":"M Harlander","year":"2014","journal-title":"Respir Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2009.09.034","article-title":"Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis","volume":"411","author":"R G Boot","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/B:BOLI.0000043025.17721.fc","article-title":"The expanding spectrum of disorders with elevated plasma chitotriosidase activity: An update","volume":"27","author":"H Michelakakis","year":"2004","journal-title":"J Inherit Metab Dis"},{"issue":"04","key":"ref25","first-page":"330","article-title":"Relationship between angiotensin-converting enzyme and lysozyme in sarcoidosis","volume":"63","author":"F K R\u00f8mer","year":"1982","journal-title":"Eur J Respir Dis"},{"issue":"06","key":"ref26","first-page":"337","article-title":"Angiotensin converting enzyme. IV. Changes in serum activity and in lysozyme concentrations as indicators of the course of untreated sarcoidosis","volume":"60","author":"C Gr\u00f6nhagen-Riska","year":"1979","journal-title":"Scand J Respir Dis"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1378\/chest.98.5.1125","article-title":"Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis","volume":"98","author":"N Keicho","year":"1990","journal-title":"Chest"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.intimp.2015.01.015","article-title":"Conventional markers in determination of activity of sarcoidosis","volume":"25","author":"S Gungor","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1378\/chest.124.1.186","article-title":"Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: A clinical evaluation","volume":"124","author":"J C Grutters","year":"2003","journal-title":"Chest"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MNM.0000000000000431","article-title":"Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis","volume":"37","author":"A Kalkanis","year":"2016","journal-title":"Nucl Med Commun"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1536\/ihj.17-695","article-title":"A multiple biomarker approach in patients with cardiac sarcoidosis","volume":"59","author":"T Kiko","year":"2018","journal-title":"Int Heart J"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1002\/ehf2.13614","article-title":"Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis","volume":"8","author":"Y Kobayashi","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/biom8030084","article-title":"YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: Comparison of markers of sarcoidosis activity","volume":"8","author":"P Uysal","year":"2018","journal-title":"Biomolecules"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"e0223897","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis","volume":"14","author":"L EM Eurelings","year":"2019","journal-title":"PLoS ONE"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","article-title":"Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers","volume":"156","author":"M W Ziegenhagen","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-14-121","article-title":"Interferon-inducible chemokines reflect severity and progression in sarcoidosis","volume":"14","author":"R Su","year":"2013","journal-title":"Respir Res"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1378\/chest.09-1975","article-title":"Comparative evaluation of serum markers in pulmonary sarcoidosis","volume":"137","author":"S Miyoshi","year":"2010","journal-title":"Chest"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00011-012-0585-9","article-title":"Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers","volume":"62","author":"G Paone","year":"2013","journal-title":"Inflamm Res"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1164\/ajrccm\/137.4.759","article-title":"Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis","volume":"137","author":"E C Lawrence","year":"1988","journal-title":"Am Rev Respir Dis"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"A DM Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis","volume":"138S","author":"M C Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000168489","article-title":"Serum levels of the soluble interleukin-2 receptor are dependent on the kidney function","volume":"12","author":"L N\u00e4ssberger","year":"1992","journal-title":"Am J Nephrol"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2017.4771","article-title":"Diagnostic value of serum-soluble interleukin 2 receptor levels vs angiotensin-converting enzyme in patients with sarcoidosis-associated uveitis","volume":"135","author":"F Groen-Hakan","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"09","key":"ref44","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1373\/49.9.1510","article-title":"Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis","volume":"49","author":"S Rothkrantz-Kos","year":"2003","journal-title":"Clin Chem"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00408-019-00219-2","article-title":"Identification of active sarcoidosis using chitotriosidase and angiotensin-converting enzyme","volume":"197","author":"M C Lopes","year":"2019","journal-title":"Lung"},{"issue":"01","key":"ref46","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis","volume":"27","author":"N J Sweiss","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ajo.2018.07.010","article-title":"Serum angiotensin-converting enzyme has a high negative predictive value in the investigation for systemic sarcoidosis","volume":"194","author":"R L Niederer","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/diagnostics11040608","article-title":"the comparative value of serum angiotensin converting enzyme (ACE) and lysozyme and the use of polyclonal antibody activation in the work-up of ocular sarcoidosis","volume":"11","author":"I Papasavvas","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/PL00007637","article-title":"Serum lysozyme levels and clinical features of sarcoidosis","volume":"177","author":"H Tomita","year":"1999","journal-title":"Lung"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000985","article-title":"Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care","volume":"29","author":"J Francesqui","year":"2023","journal-title":"Curr Opin Pulm Med"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ehf2.15058","article-title":"Prognostic role of high-sensitivity cardiac troponin T in patients with cardiac sarcoidosis: Insights from ILLUMINATE-CS","volume":"12","author":"Y Baba","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11897-024-00683-9","article-title":"Emerging biomarkers in cardiac sarcoidosis and other inflammatory cardiomyopathies","volume":"21","author":"J E Roumi","year":"2024","journal-title":"Curr Heart Fail Rep"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1536\/ihj.53.287","article-title":"Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis","volume":"53","author":"Y Baba","year":"2012","journal-title":"Int Heart J"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2015.06.021","article-title":"Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis","volume":"116","author":"R Kandolin","year":"2015","journal-title":"Am J Cardiol"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00408-024-00772-5","article-title":"Holter monitoring and cardiac biomarkers in screening for cardiac sarcoidosis","volume":"203","author":"A LM Bakker","year":"2024","journal-title":"Lung"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1007\/s00259-025-07266-3","article-title":"Relation between resting amygdala activity and cardiovascular events in patients with cardiac sarcoidosis","volume":"52","author":"S Otsuki","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1164\/rccm.202306-1054OC","article-title":"Discovery of two novel immunoepitopes and development of a peptide-based sarcoidosis immunoassay","volume":"210","author":"C Peng","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"S 64","key":"ref58","first-page":"5191","article-title":"Diagnosis of interstitial lung diseases using eNose technology","volume":"56","author":"C C Moor","year":"2020","journal-title":"Eur Respir J"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"026001","DOI":"10.1088\/1752-7163\/adac82","article-title":"Alveolar nitric oxide concentration as a potential biomarker of fibrosis and active disease in pulmonary sarcoidosis: A pilot study","volume":"19","author":"S Levra","year":"2025","journal-title":"J Breath Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1532437","DOI":"10.3389\/fmed.2025.1532437","article-title":"Upregulation of HSP90\u03b1 in the lungs and circulation in sarcoidosis","volume":"12","author":"T Isshiki","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e25108","DOI":"10.1002\/jcla.25108","article-title":"Diagnostic performance of CLEIA versus FEIA for KL-6 peripheral and alveolar concentrations in fibrotic interstitial lung diseases: A multicentre study","volume":"38","author":"M d'Alessandro","year":"2024","journal-title":"J Clin Lab Anal"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"2400277","DOI":"10.1183\/13993003.00277-2024","article-title":"Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: A nested case-control study in Sweden","volume":"64","author":"E V Arkema","year":"2024","journal-title":"Eur Respir J"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12890-024-03412-z","article-title":"The predictive effects of adiponectin and irisin hormones on diagnosis and clinical involvement of sarcoidosis","volume":"24","author":"H Kaya","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"18","key":"ref64","doi-asserted-by":"crossref","first-page":"e37103","DOI":"10.1016\/j.heliyon.2024.e37103","article-title":"Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?","volume":"10","author":"B Schrijver","year":"2024","journal-title":"Heliyon"},{"key":"ref65","first-page":"rs.3.rs-5220174","article-title":"Residential fungal \u03b2-(1,3)-D-glucan exposure is associated with decreased pulmonary function in fibrotic pulmonary sarcoidosis","author":"E M Stapleton","year":"2024","journal-title":"Res Sq"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"e20210785","DOI":"10.1084\/jem.20210785","article-title":"CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope","volume":"218","author":"S A Greaves","year":"2021","journal-title":"J Exp Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: Current use and future prospects","volume":"11","author":"R Kraaijvanger","year":"2020","journal-title":"Front Immunol"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"00672","DOI":"10.1183\/23120541.00672-2024","article-title":"Targeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis","volume":"11","author":"R Kraaijvanger","year":"2025","journal-title":"ERJ Open Res"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41467-025-56567-6","article-title":"Retrotrans-genomics identifies aberrant THE1B endogenous retrovirus fusion transcripts in the pathogenesis of sarcoidosis","volume":"16","author":"S Funaguma","year":"2025","journal-title":"Nat Commun"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41467-025-57829-z","article-title":"GWAS identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis","volume":"16","author":"S Yuan","year":"2025","journal-title":"Nat Commun"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/metabo15010007","article-title":"Investigating metabolic phenotypes for sarcoidosis diagnosis and exploring immunometabolic profiles to unravel disease mechanisms","volume":"15","author":"M M Banoei","year":"2024","journal-title":"Metabolites"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41598-025-85338-y","article-title":"Proteome-wide Mendelian randomization identifies causal plasma proteins in interstitial lung disease","volume":"15","author":"K Yu","year":"2025","journal-title":"Sci Rep"},{"issue":"16","key":"ref73","doi-asserted-by":"crossref","first-page":"12792","DOI":"10.3390\/ijms241612792","article-title":"Simultaneous assessment of mTORC1, JAK\/STAT, and NLRP3 inflammasome activation pathways in patients with sarcoidosis","volume":"24","author":"R Kraaijvanger","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: Prospects, potentials, and limitations","volume":"33","author":"G D Smith","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies","volume":"4","author":"J Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"issue":"14","key":"ref76","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"A Rajkomar","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"00106","DOI":"10.1183\/23120541.00106-2017","article-title":"Towards a global initiative for fibrosis treatment (GIFT)","volume":"3","author":"M Molina-Molina","year":"2017","journal-title":"ERJ Open Res"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2741-2030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T23:33:33Z","timestamp":1767656013000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2741-2030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":77,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2741-2030","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,10]]},"published":{"date-parts":[[2025,11,10]]}}}